When requests for adding drugs to WHODrug Global in connection with COVID-19 arose, the idea of collecting them as a Standardised Drug Grouping (SDG) was born. An SDG is a grouping of medications with one or more properties in common, say, chemical structure, or an indication. I thought this would be perfect for an SDG since many of these drugs – new and old – can differ greatly. The pandemic has resulted in a drug development landscape that’s moving fast, and it’s difficult for individual organisations to keep track of relevant medications. Creating an SDG does this for them, and since new substances are continuously being added to WHODrug Global, updates will be available every other month. My hope is that the drugs for COVID-19 SDG will be used in clinical trials as well as post-marketing safety settings, so that in the end there can be an effective and safe drug or vaccine against COVID-19.